HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warning Cites Ageless Derma's Anti-Wrinkle, Brightening Claims

This article was originally published in The Rose Sheet

Executive Summary

In a warning letter published on FDA's website May 2, the agency identifies two Ageless Derma products as unapproved new drugs due to label and website claims touting body structure/function effects. The laundry list of offending claims offers a resource for companies to use in their own claims-compliance efforts.

You may also be interested in...



Nutricosmetics Pose Intriguing Possibilities For Brands That Hit Wall With Skin-Care Claims

Statements about collagen production, maintaining cellular integrity, addressing age spots, even shrinking wrinkles and treating noncystic acne – all are viable structure/function claims for nutricosmetics, assuming there's evidence to back them up. The Rose Sheet discusses the growing opportunity with regulatory and legal experts and provides an overview of the market at present.

FDA Warnings Slow, But Anti-Aging Claims Remain Class Action Targets

The online universe is abuzz with complaints about 2016, with some ready to dub the year “worst ever.” It certainly was a rough one for anti-aging skin-care marketers, and while FDA’s warning letter activity has declined of late, consumer lawsuits continue to file challenging companies’ clock-reversing promises.

MGC Navigates Regulatory Uncertainty With Cannabis Skin Care

US regulations concerning use of cannabinoid CBD in consumer products are complex and hazily defined, representing an additional set of challenges for companies launching CBD-based skin care to an already heavily regulated market. MGC Derma does not expect FDA to come down on its CBD use per se, but the firm's specific product claims could still be subject to scrutiny.

Related Content

Topics

UsernamePublicRestriction

Register

RS019895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel